- Home
- OMER vs BTX Comparison
OMER vs BTX Comparison
Compare OMER & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | BTX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.6M | 770.3M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMER | BTX |
|---|---|---|
| Price | $17.80 | $8.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 379.8K |
| Earning Date | 05-14-2026 | 11-01-2025 |
| Dividend Yield | N/A | ★ 9.94% |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $233.22 | N/A |
| P/E Ratio | $23.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.06 | $6.13 |
| 52 Week High | $19.65 | $9.44 |
Technical Indicators
Market Signals| Indicator | OMER | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 49.96 |
| Support Level | $10.82 | $8.69 |
| Resistance Level | $19.60 | $8.94 |
| Average True Range (ATR) | 0.79 | 0.16 |
| MACD | -0.38 | -0.04 |
| Stochastic Oscillator | 45.57 | 47.01 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
About BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.